Oncogenically activated BRAF and silenced PTEN cooperate in melanoma formation and progression, resistance to BRAF/MEK inhibitors, and interference with tumor immune infiltration (suggesting that PI3K-pathway inhibition may represent a strategy in patients receiving targeted therapy in combination with immune checkpoint inhibitors) [56–59]. Here, BRAF is linked to neoplasm.